Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Investigator(s):
Theodore Nowicki, MD;
Organization: 
UCLA
NCT Number: 
NCT03240861
Disease Name: 
Sarcoma
Disease Category: 
Cancer
Trial Phases: 
Phase 1
Trial Status: 
Recruiting
Trial Contact: 

Theodore Scott Nowicki, MD, PhD

310-206-2090

TNowicki@mednet.ucla.edu

Antonio Ribas, MD

310-206-3928

aribas@mednet.ucla.edu